Categories
Change Password!
Reset Password!
In Chinese patients with painful diabetic peripheral neuropathy (pDPN) very limited information existed regarding the efficacy of pregabalin.
Pregabalin
is a gabapentinoid that was used mainly for the management of neuropathic pain.
It specifically binds to alpha-2-delta subunit to produce antiepileptic and
analgesic actions. In this study, the efficacy of pregabalin for diabetic
neuropathy has been evaluated, and it has been determined that pregabalin can
significantly reduce pain in a population of Chinese patients.
In
Chinese patients with painful diabetic peripheral neuropathy (pDPN) very
limited information existed regarding the efficacy of pregabalin.
An
11-week double-blind placebo-controlled trial was conducted in Chinese pDPN
patients randomized (1 : 1) to 300 mg/day pregabalin or placebo. The primary
outcome was set as the change from baseline to endpoint in mean pain score
(MPS; 0, no pain; 10, worst possible pain; using the mean of the last seven
daily pain scores). Secondary outcomes included weekly MPS and responder status
(MPS reduced by ≥30% or ≥50% vs. baseline). Subgroup analysis assessed patients
with severe (≥7) baseline MPS. Adverse events (AEs) were reported.
In
all, 620 patients were randomized (pregabalin, n = 313; placebo, n = 307).
Improvement in MPS with pregabalin versus placebo was not significant
(P = 0.0559). Post hoc sensitivity analyses, excluding one patient/site due to
Good Clinical Practice (GCP) non-compliance, showed pregabalin significantly
improved MPS when excluding the patient (P = 0.0448) or site (P = 0.0142).
Pregabalin significantly improved weekly MPS (P = 0.0164) and ≥50% responders
at endpoint (P = 0.0384). Improvement in the proportion of ≥30% responders, the
impression of change, pain intensity, and sleep did not differ significantly
between the treatment groups. In the severe pDPN subpopulation, pregabalin
significantly improved MPS versus placebo (P = 0.0040). The most commonly
reported AE was dizziness (9.6% vs. 3.9% with placebo).
Pregabalin did not significantly
improve the primary measure of pain in the trial. Significant reductions in MPS
were observed when excluding the GCP non-compliant patient/site and in the
severe pDPN subpopulation. Pregabalin was well tolerated in Chinese pDPN
patients.
J Diabetes. 2017 Jul 20
Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: a randomized, placebo-controlled trial.
Mu Y et al.
Comments (0)